Valeant completes Sanitas Group acquisition

MISSISSAUGA, Ontario — Canada-based drug maker Valeant Pharmaceuticals International has acquired a Kaunas, Lithuania-based specialty pharmaceutical company.

Valeant said it completed its acquisition of Sanitas Group, which operates in Central and Eastern Europe and Russia markets.

The deal, which initially was announced by Valeant in May, was valued at EUR314 million (about $450 million) in cash.